

# Olivier D Christophe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6740736/publications.pdf>

Version: 2024-02-01

70  
papers

2,850  
citations

186209

28  
h-index

175177

52  
g-index

72  
all docs

72  
docs citations

72  
times ranked

3238  
citing authors

#	ARTICLE	IF	CITATIONS
1	von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. <i>Blood</i> , 2015, 125, 2019-2028.	0.6	296
2	Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. <i>Blood</i> , 2013, 121, 3335-3344.	0.6	236
3	Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. <i>Blood</i> , 2017, 130, 2463-2468.	0.6	197
4	Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. <i>Nature Communications</i> , 2018, 9, 4098.	5.8	184
5	P-selectin glycoprotein ligand 1 and $\beta$ 2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. <i>Blood</i> , 2006, 108, 3746-3752.	0.6	152
6	A role for exposed mannose in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 8965-8970.	3.3	110
7	Macrophage LRP1 contributes to the clearance of von Willebrand factor. <i>Blood</i> , 2012, 119, 2126-2134.	0.6	99
8	Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. <i>Blood Advances</i> , 2017, 1, 2019-2031.	2.5	90
9	Liver-Specific Transcriptional Modules Identified by Genome-Wide In Silico Analysis Enable Efficient Gene Therapy in Mice and Non-Human Primates. <i>Molecular Therapy</i> , 2014, 22, 1605-1613.	3.7	71
10	Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. <i>Haematologica</i> , 2012, 97, 1855-1863.	1.7	70
11	Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia. <i>Blood</i> , 2013, 122, 2893-2902.	0.6	68
12	Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIb/IIIa. <i>Blood</i> , 2008, 112, 603-609.	0.6	67
13	Ca <sup>2+</sup> Binding to the First Epidermal Growth Factor-like Domain of Human Blood Coagulation Factor IX Promotes Enzyme Activity and Factor VIII Light Chain Binding. <i>Journal of Biological Chemistry</i> , 1996, 271, 25332-25337.	1.6	65
14	The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. <i>Blood</i> , 2014, 123, 121-125.	0.6	63
15	Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. <i>Blood</i> , 2010, 115, 4870-4877.	0.6	60
16	Identification of Galectin-1 and Galectin-3 as Novel Partners for Von Willebrand Factor. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 894-901.	1.1	59
17	Catalytic IgG from Patients with Hemophilia A Inactivate Therapeutic Factor VIII. <i>Journal of Immunology</i> , 2006, 177, 1355-1363.	0.4	45
18	Clearance of von Willebrand factor. <i>Thrombosis and Haemostasis</i> , 2008, 99, 271-278.	1.8	45

#	ARTICLE	IF	CITATIONS
19	von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin $\alpha$ IIb $\beta$ 3. <i>Journal of Clinical Investigation</i> , 2013, 123, 5071-5081.	3.9	42
20	Blood Coagulation Factor IX Residues Glu78 and Arg94 Provide a Link between Both Epidermal Growth Factor-like Domains That Is Crucial in the Interaction with Factor VIII Light Chain. <i>Journal of Biological Chemistry</i> , 1998, 273, 222-227.	1.6	41
21	Proteolytic antibodies activate factor IX in patients with acquired hemophilia. <i>Blood</i> , 2011, 117, 2257-2264.	0.6	38
22	Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1014-1023.	1.8	37
23	ON THE VERSATILITY OF VON WILLEBRAND FACTOR. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013046.	0.5	36
24	Correction of Bleeding Symptoms in von Willebrand Factor $\alpha$ 1 Deficient Mice by Liver-Expressed von Willebrand Factor Mutants. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 419-424.	1.1	35
25	A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation $\alpha$ Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1736-1740.	1.1	33
26	In Vivo Analysis of the Role of O-Glycosylations of Von Willebrand Factor. <i>PLoS ONE</i> , 2012, 7, e37508.	1.1	33
27	Macrophage scavenger receptor SR-A1 contributes to the clearance of von Willebrand factor. <i>Haematologica</i> , 2018, 103, 728-737.	1.7	32
28	A hemophilia A mouse model for the in vivo assessment of emicizumab function. <i>Blood</i> , 2020, 136, 740-748.	0.6	32
29	Network-based analysis of omics data: the LEAN method. <i>Bioinformatics</i> , 2017, 33, 701-709.	1.8	29
30	Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity. <i>Scientific Reports</i> , 2016, 6, 37953.	1.6	26
31	Role of the Gla and First Epidermal Growth Factor-like Domains of Factor X in the Prothrombinase and Tissue Factor-Factor VIIa Complexes. <i>Journal of Biological Chemistry</i> , 2003, 278, 10393-10399.	1.6	25
32	Mutations in the A3 domain of Von Willebrand factor inducing combined qualitative and quantitative defects in the protein. <i>Blood</i> , 2013, 121, 2135-2143.	0.6	25
33	Role of the $\alpha$ 1-Helix 163-170 in Factor Xa Catalytic Activity. <i>Journal of Biological Chemistry</i> , 2007, 282, 31569-31579.	1.6	23
34	LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B. <i>JCI Insight</i> , 2016, 1, e88643.	2.3	23
35	Surface Loop 199 $\alpha$ 204 in Blood Coagulation Factor IX Is a Cofactor-dependent Site Involved in Macromolecular Substrate Interaction. <i>Journal of Biological Chemistry</i> , 1999, 274, 29087-29093.	1.6	22
36	Hydrolysis of Coagulation Factors by Circulating IgG Is Associated with a Reduced Risk for Chronic Allograft Nephropathy in Renal Transplanted Patients. <i>Journal of Immunology</i> , 2008, 180, 8455-8460.	0.4	22

#	ARTICLE	IF	CITATIONS
37	Emerging Therapeutic Strategies in the Treatment of Hemophilia A. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 581-590.	1.5	22
38	The VWF/LRP4/ $\beta$ $\text{V}^23$ -axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells. <i>Cardiovascular Research</i> , 2022, 118, 622-637.	1.8	22
39	Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors. <i>EMBO Molecular Medicine</i> , 2020, 12, e11298.	3.3	20
40	Characterization of Recombinant von Willebrand Factors Mutated on Cysteine 509 or 695. <i>Thrombosis and Haemostasis</i> , 1996, 76, 453-459.	1.8	20
41	A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation. <i>Scientific Reports</i> , 2016, 6, 26306.	1.6	19
42	A factor VIII nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation. <i>Blood</i> , 2018, 132, 1193-1197.	0.6	19
43	Thermodynamic Analysis of the Interaction of Factor VIII with von Willebrand Factor. <i>Biochemistry</i> , 2012, 51, 4108-4116.	1.2	17
44	Kinesin-1 Is a New Actor Involved in Platelet Secretion and Thrombus Stability. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1037-1051.	1.1	17
45	A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor. <i>Blood</i> , 2012, 120, 2723-2732.	0.6	16
46	Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA. <i>Haematologica</i> , 2020, 105, 1129-1137.	1.7	15
47	Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia. <i>Blood</i> , 2019, 134, 1632-1644.	0.6	14
48	In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model. <i>Hepatology</i> , 2022, 75, 866-880.	3.6	12
49	Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions. <i>Blood</i> , 2017, 129, 2443-2454.	0.6	11
50	Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor. <i>Gene Therapy</i> , 2023, 30, 245-254.	2.3	11
51	Coagulation Factor X Interaction with Macrophages through Its N-Glycans Protects It from a Rapid Clearance. <i>PLoS ONE</i> , 2012, 7, e45111.	1.1	10
52	Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets. <i>Blood Advances</i> , 2018, 2, 1417-1428.	2.5	9
53	Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X. <i>Blood</i> , 2016, 127, 778-786.	0.6	8
54	Camelid-derived single-chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1087-1110.	1.0	8

#	ARTICLE	IF	CITATIONS
55	Paraoxonase-1 expression is up-regulated in Down syndrome fetal liver. <i>Biochemical and Biophysical Research Communications</i> , 2006, 346, 1303-1306.	1.0	6
56	Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice. <i>Blood</i> , 2014, 123, 3344-3353.	0.6	6
57	Development and characterization of single-domain antibodies neutralizing protease nexin-1 as tools to increase thrombin generation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2155-2168.	1.9	6
58	Biological outcome and mapping of total factor cascades in response to HIF induction during regenerative angiogenesis. <i>Oncotarget</i> , 2016, 7, 12102-12120.	0.8	6
59	A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1981-1993.	1.8	5
60	In vivo modulation of a dominant-negative variant in mouse models of von Willebrand disease type 2A. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 139-146.	1.9	5
61	Apoptotic Platelet Events Are Not Observed in Severe von Willebrand Disease-Type 2B Mutation p.V1316M. <i>PLoS ONE</i> , 2015, 10, e0143896.	1.1	4
62	VON WILLEBRAND FACTOR ABNORMALITIES STUDIED IN THE MOUSE MODEL: WHAT WE LEARNED ABOUT VWF FUNCTIONS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013047.	0.5	3
63	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells. <i>Frontiers in Immunology</i> , 2020, 11, 393.	2.2	3
64	A single-domain antibody that blocks factorVlla activity in the absence but not presence of tissue factor. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2035-2046.	1.9	1
65	Identification of von Willebrand factor D4 domain mutations in patients of Afro-Caribbean descent: In vitro characterization. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12737.	1.0	1
66	Autologous cell/gene therapy approach of hemophilia B using patient specific induced Pluripotent Stem Cells. <i>Journal of Hepatology</i> , 2018, 68, S81-S82.	1.8	0
67	Siglecs as Novel Cellular Partners for Von Willebrand Factor. <i>Blood</i> , 2010, 116, 4306-4306.	0.6	0
68	Determinants of von Willebrand Factor Function. <i>Blood</i> , 2012, 120, SCI-17-SCI-17.	0.6	0
69	Mechanisms and Therapeutic Modulation of the Bleeding Tendency in Genetically-Engineered Von Willebrand Disease Type 2B Mice. <i>Blood</i> , 2015, 126, 3516-3516.	0.6	0
70	Antithrombotic potential of a single-domain antibody enhancing the activated protein C cofactor activity of protein S. <i>Journal of Thrombosis and Haemostasis</i> , 2022, , .	1.9	0